Trump, Eli Lilly, Novo Nordisk unveil offers to chop weight problems drug costs

President Donald Trump on Thursday introduced offers with Eli Lilly and Novo Nordisk to slash the costs of a few of their weight problems medicine, together with upcoming capsules, in a landmark effort to increase entry to the expensive blockbuster therapies.

The agreements will minimize costs of so-called GLP-1 medicine for Medicare and Medicaid beneficiaries in 2026 and provide the therapies on to shoppers at a reduction on an internet site the Trump administration is launching in January known as TrumpRx.gov.

Which means Medicare will begin overlaying weight problems medicine for some sufferers for the primary time beginning mid-2026, a long-awaited transfer that would broaden the marketplace for the medicines and spur extra non-public insurers to cowl them. Sure Medicare sufferers pays a copay of $50 per 30 days for all accepted makes use of of injectable and oral GLP-1 medicine, together with diabetes and weight problems therapy.

Beginning doses of upcoming weight problems capsules from Eli Lilly and Novo Nordisk, pending approvals, will probably be $145 per 30 days for everybody getting them via Medicare, Medicaid or TrumpRx, a senior administration official who declined to be named informed reporters throughout a briefing Thursday. Novo Nordisk’s oral model of its weight problems injection Wegovy may enter the market by year-end, whereas Eli Lilly’s capsule orforglipron may launch subsequent yr.

Beginning doses of current injections like Novo’s Wegovy and Lilly’s Zepbound will probably be $350 per 30 days on TrumpRX, however will “pattern down” to $245 per 30 days over a two-year interval, one other senior administration official mentioned in the course of the briefing.

Wegovy and Zepbound haven’t been coated by Medicare for weight reduction, “they usually’ve solely hardly ever been coated by Medicaid,” Trump mentioned within the Oval Workplace. “They’ve typically value shoppers greater than $1,000 per 30 days, some much more than that. … That ends beginning right now.”

The offers are among the many most politically vital bulletins up to now within the Trump administration’s push to rein in excessive U.S. drug prices by tying them to the bottom costs overseas. As a part of the president’s “most favored nation” coverage, he has introduced offers with Pfizer, AstraZeneca and EMD Serono to promote sure medicine on to sufferers at a reduction, in change for exemptions from deliberate pharmaceutical tariffs.

“That is the most important drug in our nation, and that is why that is an important of all of the [most favored nation] bulletins we have made,” Well being and Human Providers Secretary Robert F. Kennedy Jr. mentioned in the course of the briefing. “That is going to have the most important affect on the American folks. All People, even those that should not on Medicaid, Medicare, are going to have the ability to get the identical value for his or her medicine, for his or her GLP-1s.”

Kennedy claimed the American public will lose 125 million kilos by this time subsequent yr, saying the expanded entry could have “dramatic results on human well being” within the U.S.

The listing costs of current weight problems medicine – roughly $1,000 to $1,350 per 30 days earlier than insurance coverage – are an enormous barrier for sufferers, a lot of whom may gain advantage from their capability to advertise weight reduction and ease different associated well being issues similar to cardiovascular dangers and sleep apnea. Eli Lilly and Novo Nordisk have already got applications to promote their weight reduction medicine at a reduction on to cash-paying shoppers, however the brand new agreements seem to take these efforts to spice up entry a step additional. 

Novo Nordisk and Eli Lilly have agreed to chop the worth Medicare pays for GLP-1s it already covers for diabetes and different indications, together with these medicine for weight problems, to $245 per 30 days. The businesses agreed to increase decrease authorities pricing for his or her GLP-1 medicine – $245 per 30 days throughout all different nonstarting doses – to all 50 Medicaid applications for all coated makes use of. States must choose into these costs, that means some could not.

However Medicare protection may have an even bigger affect on who will get the medicine as a result of this system covers about 66 million folks, and is the first supply of insurance coverage for folks ages 65 and above. The brand new weight problems drug protection will probably be enabled via a pilot program designed to cowl a majority of beneficiaries underneath Medicare Half D, that are this system’s prescription drug plans.

One other senior administration official mentioned round 10% of Medicare beneficiaries will probably be eligible to obtain GLP-1s for weight problems and cardiovascular and metabolic advantages. Eligible sufferers will fall into three cohorts. The primary contains those that are obese, with a physique mass index better than 27 or with prediabetes or established heart problems.

The second group is folks with weight problems – with a BMI better than 30 – and uncontrolled hypertension, kidney illness or coronary heart failure. The third group is sufferers with extreme weight problems, or anybody with a BMI better than 35.

GLP-1s for weight reduction are accepted for a wider inhabitants: individuals who have weight problems or are obese with one associated situation. The administration official mentioned, “We’re constraining the entry for sufferers that may profit clinically from it, we have labored very arduous to strike a steadiness between broad entry that simply makes positive to seize sufferers that may profit clinically.”

As a part of the offers, Eli Lilly and Novo Nordisk additionally made related pledges to those different drugmakers have made as a part of Trump’s most favored nation agreements. The businesses will assure most favored nation pricing on all new medicines they bring about to market, present that pricing to each state Medicaid program, provide no less than U.S. web costs or most favored nation pricing on practically all main care medicine on TrumpRx and share financial savings from international drug value will increase on current merchandise, one senior administration official mentioned. 

Additionally on Thursday, Eli Lilly mentioned it could decrease costs by $50 by itself direct-to-consumer platform, LillyDirect, which already provides Zepbound at a reduction to cash-paying sufferers. The multidose pen of Zepbound will probably be out there at $299 per 30 days on the lowest dose, with extra doses being priced as much as $449 per 30 days. 

Eli Lilly’s capsule, as soon as accepted, will probably be out there on the lowest dose beginning at $149 per 30 days. 

In a press release Thursday, Eli Lilly CEO David Ricks mentioned the deal marks “a pivotal second in U.S. well being care coverage and a defining milestone for Lilly,” which is targeted on “enhancing outcomes, strengthening the U.S. healthcare system, and contributing to the well being of our nation for generations to come back.”

In a separate assertion, Novo Nordisk CEO Mike Doustdar mentioned, “right now’s announcement will carry semaglutide medicines to extra American sufferers at a decrease value.” Semaglutide is the energetic ingredient in Wegovy and Ozempic.

It isn’t the primary time the federal government has floated Medicare protection of weight problems medicine. Former President Joe Biden proposed a rule on the finish of his time period that might have allowed this system to cowl these therapies, however the Trump administration in April declined to finalize the measure. 

Biden’s proposal would have prolonged entry to roughly 3.4 million Medicare beneficiaries. But it surely was controversial on the time, as it could value taxpayers as a lot as $35 billion over 9 years, a congressional evaluation discovered.

However some well being specialists contend that overlaying the medicine may remove the downstream prices concerned with treating obesity-related situations. 

Semaglutide can be included within the subsequent spherical of Medicare drug value negotiations underneath the Inflation Discount Act, which Biden signed into legislation in 2022. Trump is anticipated to unveil the brand new costs of the 15 medicine chosen for these talks by Nov. 30. 

Tirzepatide, the energetic ingredient in Eli Lilly’s Zepbound and diabetes injection Mounjaro, doubtless will not be eligible for these negotiations till the tip of the last decade.